Astrazeneca PLC 6-K, filed Sep 9, 2021
Astrazeneca PLC (AZN)
6-K
2021-09-09
For: 2021-09-09
View Original
Added on
April 02, 2026
About this 6-K
Astrazeneca PLC filed this 6-K on September 9, 2021.
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of September
2021
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Imfinzi improves survival in NSCLC in POSEIDON
9 September 2021 16:00 BST
Imfinzi and
tremelimumab with chemotherapy improved progression-free survival
by 28% and overall survival by 23% in 1st-line Stage IV non-small
cell lung cancer vs. chemotherapy
POSEIDON Phase III trial showed the addition of a short course of
tremelimumab to Imfinzi plus chemotherapy improved patient outcomes
without an increase in treatment discontinuation
Positive results from the POSEIDON Phase III trial showed
AstraZeneca's Imfinzi (durvalumab) and tremelimumab, when added to
platinum-based chemotherapy, demonstrated a statistically
significant and clinically meaningful improvement in overall
survival (OS) and progression-free survival (PFS) compared to
chemotherapy alone in the 1st-line treatment of patients with Stage
IV (metastatic) non-small cell lung cancer
(NSCLC).
These results were presented today during a Presidential Symposium
at the 2021 World Conference on Lung Cancer hosted by the
International Association for the Study of Lung Cancer
(abstract PL02.01).
Melissa Johnson, MD, Director of the Lung Cancer
Research program at Sarah Cannon Research Institute, and medical
oncologist with Tennessee Oncology, PLLC in Nashville, Tennessee,
said: "New combinations are increasingly important in
addressing the remaining unmet needs that impact patients with
metastatic non-small cell lung cancer - especially combinations
that have the potential to improve efficacy in patients with lower
PD-L1 expression and deliver the long-term survival benefits that
have been observed with CTLA-4 inhibition. The results of POSEIDON
confirm that tremelimumab added to Imfinzi and chemotherapy is an effective,
well-tolerated treatment in this setting."
Susan Galbraith, Executive Vice President, Oncology R&D, said:
"The POSEIDON data offer patients further benefit
from Imfinzi and are an important validation of our
development strategy to explore novel combinations. Adding a short
course of tremelimumab to Imfinzi for those patients already receiving
chemotherapy, reduced the risk of cancer progressing or death
by 28% compared to chemotherapy alone. The results also showed
the significant survival improvement did not compromise
tolerability in the 1st-line treatment of patients with metastatic
non-small cell lung cancer. We look forward to discussing these
data with regulatory authorities."
Patients treated with a short course of five cycles of
tremelimumab, an anti-CTLA4 antibody, over 16 weeks in addition
to Imfinzi and chemotherapy experienced a 23% reduction
in the risk of death versus a range of chemotherapy options (based
on a hazard ratio [HR] of 0.77; 95% CI 0.65-0.92; p=0.00304).
Median OS was 14.0 months versus 11.7 months for chemotherapy. An
estimated 33% of patients were alive at two years versus 22% for
chemotherapy. This treatment combination also reduced the risk of
disease progression or death by 28% compared to chemotherapy alone
(HR 0.72; 95% CI 0.60-0.86; p=0.00031) with a median PFS of 6.2
months versus 4.8 months, respectively. The combination delivered a
broadly similar safety profile to the Imfinzi and chemotherapy combination and did not
lead to an increased discontinuation of
treatment.
POSEIDON also tested the combination of Imfinzi plus chemotherapy, which demonstrated a
statistically significant improvement in PFS (HR=0.74; 95% CI
0.62-0.89; p=0.00093) versus chemotherapy alone. A positive OS
trend observed for Imfinzi plus chemotherapy did not achieve
statistical significance.
Summary of OS and
PFS1
|
|
Imfinzi + tremelimumab
+ chemotherapy
(n=338)
|
Chemotherapy
(n=337)
|
|
||
|
OS2
|
|
||||
|
Number
of patients with event (%)3
|
251
(74.3)
|
285
(84.6)
|
|
||
|
Median
OS (95% CI) (in months)
|
14.0
(11.7, 16.1)
|
11.7
(10.5, 13.1)
|
|
||
|
Hazard
ratio (95% CI)
|
0.77
(0.65-0.92)
|
|
|||
|
p-value
|
0.00304
|
|
|||
|
OS
rate at 24 months (95% CI) (%)
|
32.9
(27.9, 37.9)
|
22.1
(17.8, 26.8)
|
|
|
|
|
PFS4
|
|
||||
|
Number
of patients with event (%)5
|
238
(70.4)
|
258
(76.6)
|
|
||
|
Median
PFS (95% CI) (in months)
|
6.2
(5.0, 6.5)
|
4.8
(4.6, 5.8)
|
|
||
|
Hazard
ratio (95% CI)
|
0.72
(0.60-0.86)
|
|
|||
|
p-value
|
0.00031
|
|
|||
|
PFS
rate at 12 months (%)
|
26.6
(21.7, 31.7)
|
13.1
(9.3, 17.6)
|
|
|
|
|
|
|
|
|
||
1 Investigator-assessed. OS data cut-off date was 12 March 2021;
PFS data cut-off date was 24 July 2019
2 Median follow-up in censored patients at DCO: 34.9 months (range
0-44.5)
3 Analysis was done at 79% maturity
4 Median follow-up in censored patients at DCO: 10.3 months (range
0-23.1)
5 Analysis was done at 73% maturity
The safety profile of each Imfinzi combination was consistent with the known
profiles of the individual medicines, and no new safety signals
were identified. Grade 3 or 4 treatment-related adverse events were
experienced by 51.8% of patients treated
with Imfinzi, tremelimumab and chemotherapy and by 44.6% of
patients treated with Imfinzi plus chemotherapy, versus 44.4% for
chemotherapy. Treatment-related adverse events led to treatment
discontinuation in 15.5% of patients treated
with Imfinzi, tremelimumab and chemotherapy and 14.1% of
patients treated with Imfinzi plus chemotherapy, versus 9.9% for
chemotherapy.
Imfinzi is the only
approved immunotherapy in the curative-intent setting of
unresectable, Stage III NSCLC after chemoradiation therapy and is
the global standard of care based on the PACIFIC Phase III
trial. Imfinzi is also approved in the US, the EU, Japan
and many countries around the world for the treatment of
extensive-stage small cell lung cancer (ES-SCLC) based on the
CASPIAN Phase III trial.
Imfinzi is being further
assessed across all stages of lung cancer as part of an extensive
development programme across NSCLC and SCLC, as well as in other
tumour types. The combination of Imfinzi and tremelimumab is being tested in lung
cancer, bladder cancer and liver cancer
settings.
Stage IV NSCLC
Lung cancer is the leading cause of cancer death accounting for
about one-fifth of all cancer deaths.1 Patients
are commonly diagnosed at Stage IV, when the tumour has spread
outside of the lung.2
Lung cancer is broadly split into NSCLC and SCLC, with 80-85%
classified as NSCLC.2,3 Within
NSCLC, patients are classified as squamous, representing 25-30% of
patients, or non-squamous, the most common type representing
approximately 70-75% of NSCLC patients.2 Stage
IV is the most advanced form of lung cancer and is often referred
to as metastatic disease.4
POSEIDON
The POSEIDON trial was a randomised, open-label, multi-centre,
global, Phase III trial of Imfinzi plus platinum-based chemotherapy
or Imfinzi, tremelimumab and chemotherapy versus
chemotherapy alone in the 1st-line treatment of 1,013 patients with
metastatic NSCLC. The trial population included patients with
either non-squamous or squamous disease and the full range of PD-L1
expression levels. POSEIDON excluded patients with certain
epidermal growth factor receptor (EGFR) mutations or anaplastic
lymphoma kinase (ALK) fusions.
In the experimental arms, patients were treated with a flat dose of
1,500mg of Imfinzi with up to four cycles of chemotherapy once
every three weeks or Imfinzi and 75mg of tremelimumab with chemotherapy,
followed by maintenance treatment with Imfinzi, or Imfinzi and one dose of tremelimumab on a
once-every-four-weeks dosing schedule. In comparison, the control
arm allowed up to six cycles of chemotherapy. Pemetrexed
maintenance treatment was allowed in all arms in patients with
non-squamous disease if given during the induction phase. Nearly
all patients with non-squamous disease (95.5%) had pemetrexed and
platinum, while the majority of patients with squamous disease
receiving chemotherapy (88.3%) received gemcitabine and
platinum.
Primary endpoints included PFS and OS for
the Imfinzi plus chemotherapy arm. Key secondary
endpoints included PFS and OS in the Imfinzi plus tremelimumab and chemotherapy arm. As
both PFS endpoints were met for Imfinzi plus chemotherapy
and Imfinzi, tremelimumab and chemotherapy, the
prespecified statistical analysis plan allowed for testing OS in
the Imfinzi plus tremelimumab and chemotherapy arm. The
trial was conducted in more than 150 centres across 18 countries,
including the US, Europe, South America, Asia and South
Africa.
Imfinzi
Imfinzi (durvalumab) is a human monoclonal antibody that binds to
PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80,
countering the tumour's immune-evading tactics and releasing the
inhibition of immune responses.
In addition to approvals in ES-SCLC and unresectable, Stage III
NSCLC, Imfinzi is approved for previously treated patients with
advanced bladder cancer in several countries. Since the first
approval in May 2017, more than 100,000 patients have been treated
with Imfinzi.
As part of a broad development programme, Imfinzi is being tested as a single treatment and in
combinations with other anti-cancer treatments for patients with
NSCLC, SCLC, bladder cancer, hepatocellular carcinoma, biliary
tract cancer (a form of liver cancer), oesophageal cancer, gastric
and gastroesophageal cancer, cervical cancer, ovarian cancer,
endometrial cancer, and other solid tumours.
Tremelimumab
Tremelimumab is a human monoclonal antibody and potential new
medicine that targets the activity of cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4). Tremelimumab blocks the
activity of CTLA-4, contributing to T-cell activation, priming the
immune response to cancer and fostering cancer cell death.
Tremelimumab is being tested in a clinical trial programme in
combination with Imfinzi in NSCLC, SCLC, bladder cancer and liver
cancer.
AstraZeneca in lung cancer
AstraZeneca is working to bring patients with lung cancer closer to
cure through the detection and treatment of early-stage disease,
while also pushing the boundaries of science to improve outcomes in
the resistant and advanced settings. By defining new therapeutic
targets and investigating innovative approaches, the Company aims
to match medicines to the patients who can benefit
most.
The Company's comprehensive portfolio includes leading lung cancer
medicines and the next wave of innovations,
including Tagrisso (osimertinib) and Iressa (gefitinib); Imfinzi (durvalumab) and
tremelimumab; Enhertu (trastuzumab deruxtecan) and datopotamab
deruxtecan in collaboration with Daiichi
Sankyo; Orpathys (savolitinib) in collaboration with
HUTCHMED; as well as a pipeline of potential new medicines and
combinations across diverse mechanisms of
action.
AstraZeneca is a founding member of the Lung Ambition Alliance, a
global coalition working to accelerate innovation and deliver
meaningful improvements for people with lung cancer, including and
beyond treatment.
AstraZeneca in immunotherapy
Immunotherapy is a therapeutic approach designed to stimulate the
body's immune system to attack tumours. The Company's IO portfolio
is anchored in immunotherapies that have been designed to overcome
anti-tumour immune suppression. AstraZeneca is invested in using IO
approaches that deliver long-term survival for new groups of
patients across tumour types.
The Company is pursuing a comprehensive clinical-trial programme
that includes Imfinzi as a single treatment and in combination
with tremelimumab and
other novel antibodies in multiple tumour types, stages of disease,
and lines of treatment, and where relevant using the PD-L1
biomarker as a decision-making tool to define the best potential
treatment path for a patient. In addition, the ability to combine
the IO portfolio with radiation, chemotherapy, small, targeted
molecules from across AstraZeneca's oncology pipeline, and from
research partners, may provide new treatment options across a broad
range of tumours.
AstraZeneca in oncology
AstraZeneca is leading a revolution in oncology with the ambition
to provide cures for cancer in every form, following the science to
understand cancer and all its complexities to discover, develop and
deliver life-changing medicines to patients.
The Company's focus is on some of the most challenging cancers. It
is through persistent innovation that AstraZeneca has built one of
the most diverse portfolios and pipelines in the industry, with the
potential to catalyse changes in the practice of medicine and
transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day,
eliminate cancer as a cause of death.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
References
1. World Health
Organization. International Agency for Research on Cancer. Lung
Fact Sheet. Available at: http://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf.
Accessed September 2021.
2. Abernethy
AP, et
al. Real-world first-line
treatment and overall survival in non-small cell lung cancer
without known EGFR mutations or ALK rearrangements in US community
oncology setting. PLoS ONE. 2017;12(6):e0178420.
3. Cheema PK, et al. Perspectives on treatment advances for stage III
locally advanced unresectable non-small-cell lung
cancer. Curr Oncol. 2019;26(1):37-42.
4. Cancer.Net. Lung
Cancer - Non-Small Cell: Stages. Available
at: https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/stages.
Accessed September 2021.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date:
09 September
2021
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|